Genmab shifts to innovation-led growth with 21% revenue, 52% operating profit, $3.4B cash, Epkinly, Rina-S, and Anthropic AI ...
MedPage Today on MSN
Opportunistic Cholesterol Gene Screens: Good in Theory Only?
The ROAR trial tested the hypothesis that returning familial hypercholesterolemia-associated genetic results leads to ...
Researchers evaluated the impact of a 3-month resistance exercise program on exercise capacity and HRQOL in adults with ...
Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026Data generated will support ...
Alkermes (ALKS) shifts to fully integrated biopharma, leveraging Vibrance-2, Lybalvi growth, and Avadel buy to de-risk ...
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License ...
Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the programSupports the ...
Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis – – Approximately 65% of patients achieved PASI 90 ...
Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from ...
Investing.com -- Polyrizon Ltd (NASDAQ:PLRZ) stock gained 2.8% on Monday after the pre-clinical-stage biotechnology company announced positive results from an in-vitro study of its PL-14 Allergy ...
Formal written minutes from the U.S. FDA confirms no major concerns identified for the planned Phase 3 PANDA study of ...
Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback